Atossa Therapeutics (ATOS) Expected to Announce Earnings on Monday

Atossa Therapeutics (NASDAQ:ATOS) is expected to be releasing its earnings data before the market opens on Monday, April 7th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Therapeutics Stock Performance

Shares of NASDAQ:ATOS opened at $0.60 on Friday. Atossa Therapeutics has a 52 week low of $0.60 and a 52 week high of $1.97. The company has a market cap of $77.64 million, a PE ratio of -2.73 and a beta of 1.20. The firm has a 50 day simple moving average of $0.76 and a 200 day simple moving average of $1.07.

Institutional Investors Weigh In On Atossa Therapeutics

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE grew its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 111,475 shares of the company’s stock after acquiring an additional 37,809 shares during the period. Bank of America Corp DE owned 0.09% of Atossa Therapeutics worth $105,000 as of its most recent SEC filing. 12.74% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Ascendiant Capital Markets lifted their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Atossa Therapeutics in a research report on Wednesday, March 26th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.